By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sangamo Therapeutics (Formerly Known As Sangamo BioSciences, Inc.) 

501 Canal Boulevard
Suite A100
Richmond  California  94804  U.S.A.
Phone: 510-970-6000 Fax: 510-236-8951


Key Statistics

Ownership: Public

Web Site: Sangamo
Symbol: SGMO


Company News
Sangamo (SGMO) Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy 5/16/2017 9:12:39 AM
Sangamo (SGMO) Presents Recent Developments From Research And Clinical Programs At Annual Meeting Of The American Society Of Gene & Cell Therapy 5/15/2017 9:42:56 AM
Sangamo (SGMO) Reports First Quarter 2017 Financial Results 5/11/2017 8:38:08 AM
Pfizer (PFE) Makes a $545 Million Deal With Another Bay Area Biotech, Sangamo (SGMO) 5/11/2017 5:45:19 AM
Sangamo (SGMO) Announces First Quarter 2017 Conference Call And Webcast 5/4/2017 9:31:44 AM
Sangamo (SGMO) Announces Special Regulatory Designations From The FDA For Three Clinical Programs 5/4/2017 7:55:58 AM
Sangamo (SGMO) Founder And Genome Editing Pioneer To Retire From The Board 4/26/2017 5:54:45 AM
Sangamo Therapeutics (SGMO) Announces Presentation Of New Data Demonstrating Significant Reduction Of Tau Expression Using Proprietary ZFP Gene Regulation Technology 3/29/2017 8:29:08 AM
Sangamo Therapeutics (SGMO) Receives Orphan Drug Designation From The FDA For SB-913 Genome Editing Treatment For MPS II 3/1/2017 7:13:33 AM
Sangamo Therapeutics (SGMO) Reports Fourth Quarter And Full Year 2016 Financial Results 2/28/2017 8:29:19 AM